Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Regeneron weighs overseas price for rare hearing loss gene therapy

    April 25, 2026

    Teck quarterly profit beats estimates on record copper sales, higher prices

    April 25, 2026

    This is who’s developing Golden Dome’s orbital interceptors—if they’re ever built

    April 25, 2026
    Facebook X (Twitter) Instagram
    Addison Markets
    • Home
    • USA
    • Europe
    • Business
    • Investing
    • Tech
    • Politics
    • Contact Us
    Addison Markets
    Home»Business»The charts are showing there’s more pain ahead for healthcare stocks, says Carter Worth
    Business

    The charts are showing there’s more pain ahead for healthcare stocks, says Carter Worth

    franperez66q@protonmail.comBy franperez66q@protonmail.comApril 25, 2026No Comments2 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email


    (Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) The worst performing sector year to date is healthcare, and there is every indication there is more downside ahead. The 2-panel chart below tells the tale. The top panel is the Health Care Select Sector SPDR ETF (XLV) itself, and it is a bad technical setup. The ETF is toying with the prospect of breaking the trend line in effect since the 2025 tariff lows of a year ago, all in the context of a two-year double top formation, and a head & shoulders top formation of the past 6 months. The bottom panel depicts XLV’s relative performance to the S & P 500 Index. It is the very definition of no alpha. In fact, healthcare is making 10 year relative lows to the market. If one is long or overweight the sector, take measures. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    franperez66q@protonmail.com
    • Website

    Related Posts

    Regeneron weighs overseas price for rare hearing loss gene therapy

    April 25, 2026

    Will he stay or will he go? With criminal probe over, Fed Chair Powell faces big decision

    April 25, 2026

    Nuclear reactor company X-energy shares surge 27% in strong debut

    April 25, 2026

    A ‘sleep like a baby’ portfolio is having its best year in nearly a century

    April 25, 2026

    Cramer’s week ahead: Record highs meet a pivotal week for tech earnings

    April 25, 2026

    How the restaurant group behind NYC’s Carbone is overcoming young people shunning alcohol

    April 24, 2026
    Leave A Reply Cancel Reply

    Top Reviews
    Editors Picks

    Regeneron weighs overseas price for rare hearing loss gene therapy

    April 25, 2026

    Teck quarterly profit beats estimates on record copper sales, higher prices

    April 25, 2026

    This is who’s developing Golden Dome’s orbital interceptors—if they’re ever built

    April 25, 2026

    Hillsborough Law to progress in next parliamentary session

    April 25, 2026
    © 2026 All right reserved
    • About Us
    • Privacy Policy
    • Terms & Conditions
    • Disclaimer

    Type above and press Enter to search. Press Esc to cancel.